Pulmonary hypertension in systemic sclerosis with usual interstitial pneumonia.
Idiopathic pulmonary fibrosis
Interstitial lung disease
Non-specific interstitial pneumonia
Pulmonary hypertension
Systemic sclerosis
Usual interstitial pneumonia
Journal
Internal and emergency medicine
ISSN: 1970-9366
Titre abrégé: Intern Emerg Med
Pays: Italy
ID NLM: 101263418
Informations de publication
Date de publication:
06 2023
06 2023
Historique:
received:
22
12
2022
accepted:
31
03
2023
medline:
10
7
2023
pubmed:
18
4
2023
entrez:
17
4
2023
Statut:
ppublish
Résumé
Retrospective study comparing pulmonary hypertension risk in systemic sclerosis (SSc) and non-SSc interstitial lung disease patients with usual interstitial pneumonia (UIP) and non-specific interstitial pneumonia (NSIP). Retrospective analysis of 144 interstitial lung disease patients, 53 SSc (32 UIP and 21 NSIP) and 91 non-SSc (47 UIP and 44 NSIP). Pulmonary hypertension was diagnosed as pulmonary systolic artery pressure (PAPs) > 25 mmHg. All SSc and non-SSc patients with pulmonary hypertension were classified WHO Group 3. Pulmonary hypertension was identified in 21/32 (65.6%), 9/21 (42.8%), 14/47 (29.7%), and 28/44 (45.4%) SSc-UIP, SSc-NSIP, control-UIP, and control-NSIP groups, respectively. PAPs mean of SSc-UIP group was higher than control-UIP group (32.6 ± 9.8 vs 28.5 ± 6.6, p-value = 0.02). PAPs mean of SSc-NSIP group was lower than control-NSIP group (27.0 ± 7.1 vs 33.9 ± 8.8, p = 0.002). Frequency of patients with PAP > 25 mmHg in SSc-UIP group was 60% higher in comparison to control-UIP (OR = 1.62, 95% CI 0.51-5.16) and SSc-NSIP (OR = 1.60, 95% CI 0.45-5.70) groups. Logistic regression analysis estimating the linear trend per ten-unit increase in PAPs levels demonstrated an increment for the SSc-UIP group compared to the control-UIP (OR = 2.64, 95% CI 1.25-5.58, p = 0.01) and the control-NSIP (OR = 6.34, 95% CI 2.82-14.3, p < 0.001) groups. The case-control study confirms that pulmonary hypertension is frequently found in SSc patients and demonstrates, for the first time, a significant increased risk of pulmonary hypertension among SSc-UIP patients.
Identifiants
pubmed: 37069417
doi: 10.1007/s11739-023-03267-y
pii: 10.1007/s11739-023-03267-y
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1087-1093Informations de copyright
© 2023. The Author(s), under exclusive licence to Società Italiana di Medicina Interna (SIMI).
Références
Ciaffi J, Morabito MF, Ruscitti P et al (2021) Incidence, prevalence and mortality of systemic sclerosis in Italy: a nationwide population-based study using administrative health data. Rheumatol International 41:129–137. https://doi.org/10.1007/s00296-020-04720-3
doi: 10.1007/s00296-020-04720-3
Royle JG, Lanyon PC, Grainge MJ, Abhishek A, Pearce FA (2018) The incidence, prevalence, and survival of systemic sclerosis in the UK Clinical Practice Research Datalink. Clin Rheumatol 37:2103–2111. https://doi.org/10.1007/s10067-018-4182-3
doi: 10.1007/s10067-018-4182-3
pubmed: 29961234
pmcid: 6061074
Cottin V, Brown KK (2019) Interstitial lung disease associated with systemic sclerosis (SSc-ILD). Respiratory Res 20:13. https://doi.org/10.1186/s12931-019-0980-7
doi: 10.1186/s12931-019-0980-7
DeMizio DJ, Bernstein EJ (2019) Detection and classification of systemic sclerosis-related interstitial lung disease: a review. Curr Opin Rheumatol 31:553–560. https://doi.org/10.1097/BOR.0000000000000660
doi: 10.1097/BOR.0000000000000660
pubmed: 31415029
pmcid: 7250133
Puppo F, Negrini S, Carbone RG (2021) Pulmonary vascular injury in systemic sclerosis: diagnosis and treatment. In: Carbone RG, Puppo F, Tapson VF (eds) Pulmonary vascular disorders, 3rd edn. Nova Science Publishers, New York, pp 469–484
van den Hoogen F, Khanna D, Fransen J et al (2013) 2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 65:2737–2747. https://doi.org/10.1002/art.38098
doi: 10.1002/art.38098
pubmed: 24122180
pmcid: 3930146
Perelas A, Silver RM, Arrossi AV, Highland KB (2020) Systemic sclerosis-associated interstitial lung disease. Lancet Respir Med 8:304–320. https://doi.org/10.1016/S2213-2600(19)30480-1
doi: 10.1016/S2213-2600(19)30480-1
pubmed: 32113575
Hoffmann-Vold AM, Maher TM, Philpot EE et al (2020) The identification and management of interstitial lung disease in systemic sclerosis: evidence-based European consensus statements. Lancet Rheumatol 2:e71-83. https://doi.org/10.1016/S2665-9913(19)30144-4
doi: 10.1016/S2665-9913(19)30144-4
Benan M, Hande I, Gul O (2007) The natural course of progressive systemic sclerosis patients with interstitial lung involvement. Clin Rheumatol 26:349–354. https://doi.org/10.1007/s10067-006-0302-6
doi: 10.1007/s10067-006-0302-6
pubmed: 16636936
Wangkaew S, Euathrongchit J, Wattanawittawas P, Kasitanon N, Louthrenoo W (2016) Incidence and predictors of interstitial lung disease (ILD) in Thai patients with early systemic sclerosis: inception cohort study. Mod Rheumatol 26:588–593. https://doi.org/10.1007/s10067-020-05296-w
doi: 10.1007/s10067-020-05296-w
pubmed: 26561397
Mayes MD, Lacey JV Jr, Beebe-Dimmer J et al (2003) Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 48:2246–2255. https://doi.org/10.1002/art.11073
doi: 10.1002/art.11073
pubmed: 12905479
Steen V (2005) Advancements in diagnosis of pulmonary artery hypertension in scleroderma. Arthritis Rheum 52:3698–3700. https://doi.org/10.1002/art.21613
doi: 10.1002/art.21613
pubmed: 16320319
Stock CJW, Renzoni EA (2018) Genetic predictors of systemic sclerosis-associated interstitial lung disease: a review of recent literature. Eur J Hum Genet 26:765–777. https://doi.org/10.1038/s41431-018-0104-8
doi: 10.1038/s41431-018-0104-8
pubmed: 29476163
pmcid: 5974020
Khanna D, Tashkin DP, Denton CP, Renzoni EA, Desai SR, Varga J (2020) Etiology, risk factors, and biomarkers in systemic sclerosis with interstitial lung disease. Am J Respir Crit Care Med 201:650–660. https://doi.org/10.1164/rccm.201903-0563CI
doi: 10.1164/rccm.201903-0563CI
pubmed: 31841044
pmcid: 7068837
Jung E, Suh CH, Kim HA, Jung JY (2018) Clinical characteristics of systemic sclerosis with interstitial lung disease. Arch Rheumatol 33:322–327. https://doi.org/10.5606/ArchRheumatol.2018.6630
doi: 10.5606/ArchRheumatol.2018.6630
pubmed: 30632529
pmcid: 6328216
Liaskos C, Marou E, Simopoulou T et al (2017) Disease-related autoantibody profile in patients with systemic sclerosis. Autoimmunity 50:414–421. https://doi.org/10.1080/08916934.2017.1357699
doi: 10.1080/08916934.2017.1357699
pubmed: 28749191
Desai SR, Veeraraghavan S, Hansell DM et al (2004) CT features of lung disease in patients with systemic sclerosis: comparison with idiopathic pulmonary fibrosis and nonspecific interstitial pneumonia. Radiology 232:560–567. https://doi.org/10.1148/radiol.2322031223
doi: 10.1148/radiol.2322031223
pubmed: 15286324
Suliman YA, Dobrota R, Huscher D et al (2015) Brief report: pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease. Arthritis Rheumatol 67:3256–3261. https://doi.org/10.1002/art.39405
doi: 10.1002/art.39405
pubmed: 26316389
Winstone TA, Assayag D, Wilcox PG et al (2014) Predictors of mortality and progression in scleroderma-associated interstitial lung disease: a systematic review. Chest 146:422–436. https://doi.org/10.1378/chest.13-2626
doi: 10.1378/chest.13-2626
pubmed: 24576924
García-Hernández FJ, Castillo-Palma MJ, Tolosa-Vilella C et al (2019) Pulmonary hypertension in Spanish patients with systemic sclerosis: data from the RESCLE registry. Clin Rheumatol 38:1117–1124. https://doi.org/10.1007/s10067-018-4390-x
doi: 10.1007/s10067-018-4390-x
pubmed: 30535994
Niklas K, Niklas A, Mularek-Kubzdela T, Puszczewicz M (2018) Prevalence of pulmonary hypertension in patients with systemic sclerosis and mixed connective tissue disease. Medicine 97:e11437. https://doi.org/10.1097/MD.0000000000011437
doi: 10.1097/MD.0000000000011437
pubmed: 29995796
pmcid: 6076033
Young A, Vummidi D, Visovatti S et al (2019) Prevalence, treatment, and outcomes of coexistent pulmonary hypertension and interstitial lung disease in systemic sclerosis. Arthritis Rheumatol 71:1339–1349. https://doi.org/10.1002/art.40862
doi: 10.1002/art.40862
pubmed: 30762947
pmcid: 6663644
Coghlan JG, Wolf M, Distler O et al (2018) Incidence of pulmonary hypertension and determining factors in patients with systemic sclerosis. Eur Respir J 51:1701197. https://doi.org/10.1183/13993003.01197-2017
doi: 10.1183/13993003.01197-2017
pubmed: 29563168
Naranjo M, Hassoun PM (2021) Systemic sclerosis-associated pulmonary hypertension: spectrum and impact. Diagnostics 11:911. https://doi.org/10.3390/diagnostics11050911
doi: 10.3390/diagnostics11050911
pubmed: 34065226
pmcid: 8161029
Hinchcliff M, Fischer A, Schiopu E, Steen VD (2011) Pulmonary hypertension assessment and recognition of outcomes in scleroderma (PHAROS): baseline characteristics and description of study population. J Rheumatol 8:2172–2179. https://doi.org/10.3899/jrheum.101243
doi: 10.3899/jrheum.101243
Vandecasteele E, De Pauw M, De Keyser F et al (2016) Six-minute walk test in systemic sclerosis: a systematic review and meta-analysis. Int J Cardiol 212:265–273. https://doi.org/10.1016/j.ijcard.2016.03.084
doi: 10.1016/j.ijcard.2016.03.084
pubmed: 27057932
Le Gouellec N, Duhamel A, Perez T et al (2017) Predictors of lung function test severity and outcome in systemic sclerosis-associated interstitial lung disease. PLoS ONE 12:e0181692. https://doi.org/10.1371/journal.pone.0181692
doi: 10.1371/journal.pone.0181692
pubmed: 28763468
pmcid: 5538660
Mathai SC, Hummers LK, Champion HC et al (2009) Survival in pulmonary hypertension associated with the scleroderma spectrum of diseases: impact of interstitial lung disease. Arthritis Rheum 60:569–577. https://doi.org/10.1002/art.24267
doi: 10.1002/art.24267
pubmed: 19180517
Del-Castillo AG, Meseguer ML, Fonollosa-Pla V et al (2022) Impact of interstitial lung disease on the survival of systemic sclerosis with pulmonary artery hypertension. Sci Rep 2:5289. https://doi.org/10.1038/s41598-022-09353-z
doi: 10.1038/s41598-022-09353-z
Michelfelder M, Becker M, Riedlinger A et al (2017) Interstitial lung disease increases mortality in systemic sclerosis patients with pulmonary artery hypertension without affecting hemodynamics and exercise capacity. Clin Rheumatol 36:381–390. https://doi.org/10.1007/s10067-016-3504-6
doi: 10.1007/s10067-016-3504-6
pubmed: 28028682
Trad S, Amoura Z, Beigelman C et al (2006) Pulmonary artery hypertension is a major mortality factor in diffuse systemic sclerosis, independent of interstitial lung disease. Arthritis Rheum 54:184–191. https://doi.org/10.1002/art.21538
doi: 10.1002/art.21538
pubmed: 16385514
Le Pavec J, Girgis RE, Lechtzin N et al (2011) Systemic sclerosis–related pulmonary hypertension associated with interstitial lung disease: impact of pulmonary arterial hypertension therapies. Arthritis Rheum 63:2456–2464. https://doi.org/10.1002/art.30423
doi: 10.1002/art.30423
pubmed: 21538327
Brown AN, Strange C (2009) Connective tissue disease and vasculitis-associated interstitial lung disease. In: Baughman RP, Carbone RG, Bottino G (eds) Pulmonary arterial hypertension and interstitial lung diseases, 12th edn. Humana Press, New York, pp 159–175
doi: 10.1007/978-1-60327-074-8_8
Hsu VM, Chung L, Hummers LK et al (2014) Development of pulmonary hypertension in a high-risk population with systemic sclerosis in the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort study. Semin Arthr Rheum 44:55–62. https://doi.org/10.1016/j.semarthrit.2014.03.002
doi: 10.1016/j.semarthrit.2014.03.002
Fischer A, Swigris J, Bolster MB et al (2014) Pulmonary hypertension and interstitial lung disease within PHAROS: impact of extent of fibrosis and pulmonary physiology on cardiac haemodynamic parameters. Clin Exp Rheumatol 32(Suppl 86):S109–S114
Launay D, Humbert M, Berezne A et al (2011) Clinical characteristics and survival in systemic sclerosis-related pulmonary hypertension associated with interstitial lung disease. Chest 140:1016–1024. https://doi.org/10.1378/chest.10-2473
doi: 10.1378/chest.10-2473
pubmed: 21474572
Raghu G, Remy-Jardin M, Myers JL et al (2018) Diagnosis of idiopathic pulmonary fibrosis: an official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198:e44–e68. https://doi.org/10.1164/rccm.201807-1255ST
doi: 10.1164/rccm.201807-1255ST
pubmed: 30168753
Raghu G, Remy-Jardin M, Richeldi L et al (2022) Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults an official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med 205:e18–e47. https://doi.org/10.1164/rccm.202202-0399ST
doi: 10.1164/rccm.202202-0399ST
pubmed: 35486072
pmcid: 9851481
Korevaar DA, Colella S, Fally M et al (2022) European Respiratory Society guidelines on transbronchial lung cryobiopsy in the diagnosis of interstitial lung diseases. Eur Respir J 60:2200425. https://doi.org/10.1183/13993003.00425-2022
doi: 10.1183/13993003.00425-2022
pubmed: 35710261
Tzilas V, Tzouvelekis A, Bouros E et al (2019) Diagnostic value of BAL lymphocytosis in patients with indeterminate for usual interstitial pneumonia imaging pattern. Eur Resp J 54:1901144. https://doi.org/10.1183/13993003.01144-2019
doi: 10.1183/13993003.01144-2019
Caron M, Hoa S, Hudson M, Schwartzman K, Steele R (2018) Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease. Eur Respir Rev 27:170102. https://doi.org/10.1183/16000617.0102-2017
doi: 10.1183/16000617.0102-2017
pubmed: 29769294
pmcid: 9488607
Graham BL, Brusasco V, Burgos F et al (2016) 2017 ERS/ATS standards for single-breath carbon monoxide uptake in the lung. Eur Respir J 49:1600016. https://doi.org/10.1183/13993003.00016-2016
doi: 10.1183/13993003.00016-2016
Culver BH, Graham BL, Coates AL et al (2017) Recommendations for a standardized pulmonary function report an official American Thoracic Society Technical Statement. Am J Respir Crit Care Med 196:1463–1472. https://doi.org/10.1164/rccm.201710-1981ST
doi: 10.1164/rccm.201710-1981ST
pubmed: 29192835
Parasuraman S, Walker S, Loudon BL et al (2016) Assessment of pulmonary artery pressure by echocardiography—a comprehensive review. Int J Cardiol Heart Vasc 12:45–51. https://doi.org/10.1016/j.ijcha.2016.05.011
doi: 10.1016/j.ijcha.2016.05.011
pubmed: 28616542
pmcid: 5454185
Augustine DX, Coates-Bradshaw LD, Willis J et al (2018) Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography. Echo Res Pract 5:G11–G24. https://doi.org/10.1530/ERP-17-0071
doi: 10.1530/ERP-17-0071
pubmed: 30012832
pmcid: 6055509
Wells AU, Hirani N, on behalf of the British Thoracic Society Interstitial Lung Disease Guideline Group, a subgroup of the British Thoracic Society Standards of Care Committee, in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society (2008) Interstitial lung disease guideline: the British Thoracic Society in collaboration with the Thoracic Society of Australia and New Zealand and the Irish Thoracic Society. Thorax 63(Suppl V):v1–v58. https://doi.org/10.1136/thx.2008.101691
doi: 10.1136/thx.2008.101691
pubmed: 18757459
Galie N, Humbert M, Vachiery JL et al (2016) 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT). Eur Heart J 37:67–119. https://doi.org/10.1093/eurheartj/ehv317
doi: 10.1093/eurheartj/ehv317
pubmed: 26320113
Almaaitah S, Highland KB, Tonelli AR (2020) Management of pulmonary artery hypertension in patients with systemic sclerosis. Integr Blood Press Control 13:15–29. https://doi.org/10.2147/IBPC.S232038
doi: 10.2147/IBPC.S232038
pubmed: 32280271
pmcid: 7125406
Carbone RG, Privitera V, Montanaro F, Monselise A, Ghio R (2007) Emerging indicators of survival in cellular and fibrotic nonspecific interstitial pneumonia. Chest 132:457. https://doi.org/10.1378/chest.132.4
doi: 10.1378/chest.132.4
Jandali B, Salazar GA, Hudson M et al (2022) The effect of anti-Scl-70 antibody determination method on its predictive significance for interstitial lung disease progression in systemic sclerosis. ACR Open Rheumatol 4:345–351. https://doi.org/10.1002/acr2.11398
doi: 10.1002/acr2.11398
pubmed: 35048554
pmcid: 8992461
Humbert M, Kovacs G, Hoeper MM et al (2022) 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J 43:3618–3731. https://doi.org/10.1093/eurheartj/ehac237
doi: 10.1093/eurheartj/ehac237
pubmed: 36017548